MAYNE Pharma and Mithra Pharmaceuticals announced the launch of Haloette (etonogestrel and ethinyl estradiol), a vaginal hormonal contraceptive ring into the US market.
The Haloette contraceptive is a generic version of Nuvaring.
According to IQVIA, Nuvaring US brand and generic sales were approximately US$564m for the 12 months ended Nov 2022.
Under the terms of the long-term license and supply agreement, Mayne Pharma will pay Mithra EUR1.6m.
Mayne Pharma's CEO Shawn O'Brien was pleased about the Haloette launch and said this is another example of Mayne's commitment to providing women with more contraceptive choice.
"Mayne Pharma continues to expand its women's health portfolio with the recent launch of Nextstellis (estetrol/drospirenone) in the US and Australia, and its new license agreement for Annovera, Imvexxy and Bijuva from TherapeuticsMD."
While Mithra's CEO Leon Van Rompay said: "We are pleased to start the year with the commercial launch of our affordable contraceptive alternative in the US, the world's largest pharmaceutical market.
"This key milestone has been reached thanks to the support of our Mithra CDMO, highlighting its unique expertise in developing and manufacturing complex pharmaceutical devices."
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Jan 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Jan 23
